{Reference Type}: Journal Article
{Title}: PROX1 drives neuroendocrine plasticity and liver metastases in prostate cancer.
{Author}: Liu C;Chen J;Cong Y;Chen K;Li H;He Q;Chen L;Song Y;Xing Y;
{Journal}: Cancer Lett
{Volume}: 597
{Issue}: 0
{Year}: 2024 Aug 10
{Factor}: 9.756
{DOI}: 10.1016/j.canlet.2024.217068
{Abstract}: With the widespread use of anti-androgen therapy, such as abiraterone and enzalutamide, the incidence of neuroendocrine prostate cancer (NEPC) is increasing. NEPC is a lethal form of prostate cancer (PCa), with a median overall survival of less than one year after diagnosis. In addition to the common bone metastases seen in PCa, NEPC exhibits characteristics of visceral metastases, notably liver metastasis, which serves as an indicator of a poor prognosis clinically. Key factors driving the neuroendocrine plasticity of PCa have been identified, yet the underlying mechanism behind liver metastasis remains unclear. In this study, we identified PROX1 as a driver of neuroendocrine plasticity in PCa, responsible for promoting liver metastases. Mechanistically, anti-androgen therapy alleviates transcriptional inhibition of PROX1. Subsequently, elevated PROX1 levels drive both neuroendocrine plasticity and liver-specific transcriptional reprogramming, promoting liver metastases. Moreover, liver metastases in PCa induced by PROX1 depend on reprogrammed lipid metabolism, a disruption that effectively reduces the formation of liver metastases.